{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T19:24:02Z","timestamp":1740165842901,"version":"3.37.3"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T00:00:00Z","timestamp":1679011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Two rapid, smart and validated stability indicating HPLC and TLC techniques were developed to determine atenolol (ATE) and lercanidipine HCl (LER) simultaneously in their pharmaceutical formulation. HPLC chromatographic separation was implemented by using Microsorb C18 (250\u2009\u00d7\u20094.6\u00a0mm, 5\u00a0\u03bcm) column, with mobile phase of acetonitrile and 20\u00a0mM potassium dihydrogen phosphate buffer pH\u00a03.5 adjusted by orthophosphoric acid in the ratio of (65:35, v\/v) at a flow rate of 1.2\u00a0mL\/min at 240\u00a0nm also the injection volume adjusted to be 30\u00a0\u03bcL. These selected conditions effectively separated ATE and LER at a retention time of 2 and 6.7\u00a0min, respectively, by isocratic elution mode without any interference from the obtained degradation products of LER. The densitometric determination was performed by using precoated silica gel 60F254 aluminum plates and chloroform, methanol and triethylamine (11.3:1.3: 0.3, by volume) as a developing system. The detection wavelength for simultaneous estimation of both drugs was 240\u00a0nm in the presence of the oxidative product of LER. The RF values for ATE and LER were 0.22 and 0.78, respectively. The calibration curves of both techniques were constructed with linearity ranges of (5\u201355)\u00a0\u03bcg.mL\u22121 and (1\u201355)\u00a0\u03bcg.mL\u22121 for both ATE and LER, respectively, for HPLC determination. While for TLC, the linearity ranges were (1\u20134)\u00a0\u03bcg\/band and (0.2\u20131.4)\u00a0\u03bcg\/band for ATE and LER, respectively. LER degradation products were characterized using UPLC\/MS and the suggested mechanisms and degradation pathways were introduced.<\/jats:p>","DOI":"10.1093\/chromsci\/bmad018","type":"journal-article","created":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T13:24:36Z","timestamp":1679059476000},"page":"264-272","source":"Crossref","is-referenced-by-count":1,"title":["Comprehensive and Validated Chromatographic Techniques for the Estimation of Lercanidipine Hydrochloride and Atenolol in Bulk and Combined Dosage Form in the Presence of Lercanidipine Degradation Products with LC\/MS Characterization"],"prefix":"10.1093","volume":"62","author":[{"given":"Shereen A","family":"Boltia","sequence":"first","affiliation":[{"name":"Analytical Chemistry Department , Faculty of Pharmacy, , Kasr El-Aini St., P.O. Box 11562, Cairo , Egypt"},{"name":"Cairo University , Faculty of Pharmacy, , Kasr El-Aini St., P.O. Box 11562, Cairo , Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taghreed A","family":"Fattah","sequence":"additional","affiliation":[{"name":"Pharmaceutical Chemistry Department, National Organization for Drug Control and Research (NODCAR) , Aguza, Giza , Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3563-2724","authenticated-orcid":false,"given":"Marwa T","family":"Saad","sequence":"additional","affiliation":[{"name":"Pharmaceutical Chemistry Department, National Organization for Drug Control and Research (NODCAR) , Aguza, Giza , Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hala E","family":"Zaazaa","sequence":"additional","affiliation":[{"name":"Analytical Chemistry Department , Faculty of Pharmacy, , Kasr El-Aini St., P.O. Box 11562, Cairo , Egypt"},{"name":"Cairo University , Faculty of Pharmacy, , Kasr El-Aini St., P.O. Box 11562, Cairo , Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,3,17]]},"reference":[{"key":"2024032511260572400_ref1"},{"key":"2024032511260572400_ref2"},{"issue":"20","key":"2024032511260572400_ref3","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1080\/10826070600983393","article-title":"Validated reversed-phase HPLC method for the determination of atenolol in the presence of its major degradation product","volume":"29","author":"Ceresole","year":"2006","journal-title":"Journal of Liquid Chromatography & Related Technologies"},{"issue":"2","key":"2024032511260572400_ref4","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.microc.2011.05.022","article-title":"Characterization of atenolol transformation products in ozonation by using rapid resolution high-performance liquid chromatography\/quadrupole-time-of-flight mass spectrometry","volume":"99","author":"Tay","year":"2011","journal-title":"Microchemical Journal"},{"issue":"4","key":"2024032511260572400_ref5","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.jpba.2009.01.014","article-title":"Compatibility of atenolol with excipients: LC\u2013MS\/TOF characterization of degradation\/interaction products, and mechanisms of their formation","volume":"49","author":"Kumar","year":"2009","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"issue":"3","key":"2024032511260572400_ref6","doi-asserted-by":"crossref","first-page":"381","DOI":"10.4103\/0250-474X.70490","article-title":"A stability-indicating HPLC method for assay of lercanidipine hydrochloride in tablets and for determining content uniformity","volume":"72","author":"Kaila","year":"2010","journal-title":"Indian Journal of Pharmaceutical Sciences"},{"issue":"2","key":"2024032511260572400_ref7","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3797\/scipharm.1310-10","article-title":"A fast, stability-indicating, and validated liquid chromatography method for the purity control of lercanidipine hydrochloride in tablet dosage form","volume":"82","author":"Mehta","year":"2014","journal-title":"Scientia Pharmaceutica"},{"issue":"2","key":"2024032511260572400_ref8","doi-asserted-by":"crossref","first-page":"197","DOI":"10.5530\/ijpi.2020.2.36","article-title":"A stability indicating validated method for the determination of lercanidipine using reverse phase high performance liquid chromatography","volume":"10","author":"Mondal","year":"2020","journal-title":"International Journal of Pharmaceutical Investigation"},{"issue":"4","key":"2024032511260572400_ref9","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/22297928.2014.971132","article-title":"Stability study of the calcium channel blocker lercanidipine and its determination by reversed phase chromatography in pharmaceutical formulation and plasma","volume":"4","author":"Tawakkol","year":"2014","journal-title":"Analytical Chemistry Letters"},{"issue":"1","key":"2024032511260572400_ref10","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/10826076.2011.647191","article-title":"Development and validation of stability indicating RP-HPLC method for analysis of lercanidipine in bulk drug and microemulsion formulation","volume":"36","author":"Parmar","year":"2012","journal-title":"Journal of Liquid Chromatography & Related Technologies"},{"issue":"1","key":"2024032511260572400_ref11","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jpba.2005.11.018","article-title":"Investigation on the photochemical stability of lercanidipine and its determination in tablets by HPLC\u2013UV and LC\u2013ESI\u2013MS\/MS","volume":"41","author":"Fiori","year":"2006","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"issue":"13","key":"2024032511260572400_ref12","first-page":"404","article-title":"Bio analytical method development and validation for simultaneous estimation of lercanidipine and atenolol in human plasma by using RP-HPLC","volume":"6","author":"Gokul","year":"2017","journal-title":"World Journal of Pharmaceutical Research"},{"issue":"7","key":"2024032511260572400_ref13","first-page":"3586","article-title":"A validated lercanidipine hydrochloride RP-LC-DAD method for simultaneous estimation of atenolol in tablet dosage form and its stress degradation study","volume":"5","author":"Mehmet","year":"2012","journal-title":"Journal of Pharmaceutical Research"},{"issue":"2","key":"2024032511260572400_ref14","first-page":"766","article-title":"Development and validation of a RP-HPLC method for the simultaneous estimation of atenolol and Lercanidipine hydrochloride in pharmaceutical dosage forms","volume":"3","author":"Jain","year":"2011","journal-title":"Development"},{"issue":"1","key":"2024032511260572400_ref15","first-page":"37","article-title":"Development and validation of lercanidipine hydrochloride and atenolol by using RP-HPLC and UV spectroscopy","volume":"1","author":"Bansode","year":"2014","journal-title":"Indian Journal of Pharmacy and Pharmacology"},{"issue":"4","key":"2024032511260572400_ref16","first-page":"376","article-title":"A stability-indicating high performance liquid chromatographic assay for the simultaneous determination of atenolol and lercanidipine hydrochloride in tablets","volume":"73","author":"Kaila","year":"2011","journal-title":"Indian Journal of Pharmaceutical Sciences"},{"issue":"6","key":"2024032511260572400_ref17","first-page":"752","article-title":"Method development and validation of stability indicating RP-HPLC method for simultaneous estimation of atenolol and lercanidipine in bulk and its pharmaceutical formulations","volume":"2","author":"Gade","year":"2014","journal-title":"Open Journal of Advanced Drug Delivery"},{"issue":"3","key":"2024032511260572400_ref18","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1556\/AChrom.20.2008.3.12","article-title":"Simultaneous TLC-densitometric analysis of atenolol and lercanidipine hydrochloride in tablets","volume":"20","author":"Deore","year":"2008","journal-title":"Acta Chromatographica"},{"issue":"2","key":"2024032511260572400_ref19","first-page":"125","article-title":"HPLC method development and validation of lercanidipine HCL and atenolol, characterization of its degradants by LC-MS\/MS","volume":"14","author":"Ptsrkp","year":"2022","journal-title":"International Journal of Applied Pharmaceutics"},{"issue":"2","key":"2024032511260572400_ref20","first-page":"84","article-title":"Simultaneous spectrophotometric estimation of lercanidipine hydrochloride and atenolol in tablet dosage form","volume":"6","author":"Jain","year":"2011","journal-title":"Eurasian Journal of Analytical Chemistry"},{"issue":"1","key":"2024032511260572400_ref21","first-page":"73","article-title":"Simultaneous spectrophotometric estimation of atenolol and lercanidipine hydrochloride in combined dosage form by ratio derivative and dual wavelength method","volume":"3","author":"Vishnu","year":"2010","journal-title":"International Journal of Pharmaceutical Sciences Review and Research"},{"issue":"4","key":"2024032511260572400_ref22","first-page":"398","article-title":"Development and validation of method for simultaneous estimation of atenolol and lercanidipine from tablet dosage form by second order derivative spectroscopy","volume":"2","author":"Bhatia","year":"2009","journal-title":"Asian Journal of Research in Chemistry"},{"issue":"4","key":"2024032511260572400_ref23","doi-asserted-by":"crossref","first-page":"172","DOI":"10.18579\/jpcrkc\/2010\/9\/4\/79517","article-title":"Simultaneous spectrophotometric estimation of atenolol and lercanidipine hydrochloride in combined dosage form","volume":"9","author":"Rashmi","year":"2010","journal-title":"Journal of Pharmaceutical Research"},{"volume-title":"The British Pharmacopeia","year":"2019","key":"2024032511260572400_ref24"},{"key":"2024032511260572400_ref25"},{"issue":"4","key":"2024032511260572400_ref26","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/jaoacint\/qsaa008","article-title":"Validated stability indicating chromatographic methods for quantification of imidocarb dipropionate; application for the determination of its residues in bovine meat and milk samples","volume":"103","author":"Sedik","year":"2020","journal-title":"Journal of AOAC International"},{"volume-title":"United States Pharmacopeia and National Formulary (USP 40-NF 35)","year":"2017","key":"2024032511260572400_ref27"},{"year":"2005","key":"2024032511260572400_ref28"}],"container-title":["Journal of Chromatographic Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/chromsci\/article-pdf\/62\/3\/264\/57072746\/bmad018.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/chromsci\/article-pdf\/62\/3\/264\/57072746\/bmad018.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T11:27:49Z","timestamp":1711366069000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/chromsci\/article\/62\/3\/264\/7079714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,17]]},"references-count":28,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3,17]]},"published-print":{"date-parts":[[2024,3,23]]}},"URL":"https:\/\/doi.org\/10.1093\/chromsci\/bmad018","relation":{},"ISSN":["0021-9665","1945-239X"],"issn-type":[{"type":"print","value":"0021-9665"},{"type":"electronic","value":"1945-239X"}],"subject":[],"published-other":{"date-parts":[[2024,3]]},"published":{"date-parts":[[2023,3,17]]}}}